221 related articles for article (PubMed ID: 24931162)
41. Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice.
Lan L; Holland JD; Qi J; Grosskopf S; Rademann J; Vogel R; Györffy B; Wulf-Goldenberg A; Birchmeier W
EMBO J; 2015 Jun; 34(11):1493-508. PubMed ID: 25736378
[TBL] [Abstract][Full Text] [Related]
42. Protein-tyrosine Phosphatase and Kinase Specificity in Regulation of SRC and Breast Tumor Kinase.
Fan G; Aleem S; Yang M; Miller WT; Tonks NK
J Biol Chem; 2015 Jun; 290(26):15934-47. PubMed ID: 25897081
[TBL] [Abstract][Full Text] [Related]
43. CD44 regulates cell proliferation, migration, and invasion via modulation of c-Src transcription in human breast cancer cells.
Nam K; Oh S; Lee KM; Yoo SA; Shin I
Cell Signal; 2015 Sep; 27(9):1882-94. PubMed ID: 25979842
[TBL] [Abstract][Full Text] [Related]
44. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
45. Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Gautam J; Banskota S; Lee H; Lee YJ; Jeon YH; Kim JA; Jeong BS
Exp Mol Med; 2018 Sep; 50(9):1-14. PubMed ID: 30185799
[TBL] [Abstract][Full Text] [Related]
46. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
[TBL] [Abstract][Full Text] [Related]
47. SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc epsilon RI-induced activation of Fyn and Erk pathways leading to TNF alpha release from bone marrow-derived mast cells.
McPherson VA; Sharma N; Everingham S; Smith J; Zhu HH; Feng GS; Craig AW
J Immunol; 2009 Oct; 183(8):4940-7. PubMed ID: 19786542
[TBL] [Abstract][Full Text] [Related]
48. CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.
Wright HJ; Hou J; Xu B; Cortez M; Potma EO; Tromberg BJ; Razorenova OV
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6556-E6565. PubMed ID: 28739932
[TBL] [Abstract][Full Text] [Related]
49. Role of the protein tyrosine phosphatase Shp2 in homeostasis of the intestinal epithelium.
Yamashita H; Kotani T; Park JH; Murata Y; Okazawa H; Ohnishi H; Ku Y; Matozaki T
PLoS One; 2014; 9(3):e92904. PubMed ID: 24675817
[TBL] [Abstract][Full Text] [Related]
50. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment.
Zhang SQ; Yang W; Kontaridis MI; Bivona TG; Wen G; Araki T; Luo J; Thompson JA; Schraven BL; Philips MR; Neel BG
Mol Cell; 2004 Feb; 13(3):341-55. PubMed ID: 14967142
[TBL] [Abstract][Full Text] [Related]
51. Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR/Src/PI3-K Complex Assembly.
Giovannelli P; Di Donato M; Auricchio F; Castoria G; Migliaccio A
Sci Rep; 2019 Mar; 9(1):4490. PubMed ID: 30872694
[TBL] [Abstract][Full Text] [Related]
52. SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer.
Chen H; Libring S; Ruddraraju KV; Miao J; Solorio L; Zhang ZY; Wendt MK
Oncogene; 2020 Dec; 39(49):7166-7180. PubMed ID: 33033382
[TBL] [Abstract][Full Text] [Related]
53. Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.
Chen X; Shu C; Li W; Hou Q; Luo G; Yang K; Wu X
J Med Chem; 2022 May; 65(9):6729-6747. PubMed ID: 35447031
[TBL] [Abstract][Full Text] [Related]
54. PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.
Glondu-Lassis M; Dromard M; Lacroix-Triki M; Nirdé P; Puech C; Knani D; Chalbos D; Freiss G
Cancer Res; 2010 Jun; 70(12):5116-26. PubMed ID: 20501847
[TBL] [Abstract][Full Text] [Related]
55. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
[TBL] [Abstract][Full Text] [Related]
56. Protein tyrosine phosphatase SHP2 promotes invadopodia formation through suppression of Rho signaling.
Tsai WC; Chen CL; Chen HC
Oncotarget; 2015 Sep; 6(27):23845-56. PubMed ID: 26204488
[TBL] [Abstract][Full Text] [Related]
57. Shp2 acts downstream of SDF-1alpha/CXCR4 in guiding granule cell migration during cerebellar development.
Hagihara K; Zhang EE; Ke YH; Liu G; Liu JJ; Rao Y; Feng GS
Dev Biol; 2009 Oct; 334(1):276-84. PubMed ID: 19635473
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells.
Zhou XD; Agazie YM
Cell Death Differ; 2008 Jun; 15(6):988-96. PubMed ID: 18421299
[TBL] [Abstract][Full Text] [Related]
59. Thyroid Cancer Detection by Ultrasound Molecular Imaging with SHP2-Targeted Perfluorocarbon Nanoparticles.
Hu Z; Yang B; Li T; Li J
Contrast Media Mol Imaging; 2018; 2018():8710862. PubMed ID: 29706844
[TBL] [Abstract][Full Text] [Related]
60. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth.
Patel Y; Shah N; Lee JS; Markoutsa E; Jie C; Liu S; Botbyl R; Reisman D; Xu P; Chen H
Oncotarget; 2016 Apr; 7(14):18295-308. PubMed ID: 26918448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
